Final answer:
Neumega (oprelvekin) increases the platelet count as part of its therapeutic action. A platelet count of 250,000mm³ following administration of oprelvekin indicates that the medication is effective.
Step-by-step explanation:
The medication Neumega (oprelvekin) is used to prevent severe thrombocytopenia and to reduce the need for platelet transfusions after myelosuppressive chemotherapy. Oprelvekin is a recombinant form of human interleukin-11 and falls under the category of Colony-stimulating factors (CSFs), which are glycoproteins that stimulate the proliferation of various types of blood cells.
In this context, the desired effect of oprelvekin is to increase the platelet count. Therefore, among the given findings, a platelet count of 250,000mm³ would suggest that the medication is having its desired effect in a client receiving chemotherapy for prostate cancer.